The FDA has approved the oral treatment for opioid-induced constipation naloxegol (Movantik), according to a Gastroenterology & Endoscopy News report.
Movantik is designed for adults with chronic non-cancer pain. The drug is a peripherally acting mu-opiod-receptor antagonist used to decrease the constipation side effect of opioids, according to the report.
More articles on gastroenterology:
19 things to know about GI compensation & satisfaction in 2014
AGA releases new tool for Crohn's disease treatment
How has the Obama presidency affected the field of GI?
Movantik is designed for adults with chronic non-cancer pain. The drug is a peripherally acting mu-opiod-receptor antagonist used to decrease the constipation side effect of opioids, according to the report.
More articles on gastroenterology:
19 things to know about GI compensation & satisfaction in 2014
AGA releases new tool for Crohn's disease treatment
How has the Obama presidency affected the field of GI?